Cytometry Part B: Clinical Cytometry 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.---
Cytometry Part B: Clinical Cytometry,Volume 94, Issue 1, Page 1-10, January 2018. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Source Type: research
ICCS/ESCCA consensus guidelines to detect GPI ‐deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 4 – assay validation and quality assurance
Over the past six years, a diverse group of stakeholders have put forth recommendations regarding the analytical validation of flow cytometric methods and described in detail the differences between cell‐based and traditional soluble analyte assay validations. This manuscript is based on these general recommendations as well as the published experience of experts in the area of PNH testing. The goal is to provide practical assay‐specific guidelines for the validation of high‐sensitivity flow cytometric PNH assays. Examples of the reports and validation data described herein are provided in Supporting Information. © ...
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: Teri Oldaker, Liam Whitby, Maryam Saber, Jeannine Holden, Paul K Wallace, Virginia Litwin Tags: ICCS/ESCCA PNH Guidelines Source Type: research
ICCS/ESCCA consensus guidelines to detect GPI ‐deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 – reagent selection and assay optimization for high‐sensitivity testing
Since publication in 2010 of the International Clinical Cytometry Society (ICCS) Consensus Guidelines for detection of Paroxysmal nocturnal hemoglobinuria (PNH) by flow cytometery, a great deal of work has been performed to develop, optimize, and validate a number of high‐sensitivity assays to detect PNH phenotypes in both red blood cells (RBCs) and white blood cells (WBCs, neutrophils, and monocytes). This section (Part 2) of the updated ICCS PNH Consensus Guidelines will focus on specific instrument setup for these PNH assays, the identification and proper testing of appropriate antibody conjugates and combinations the...
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: D. Robert Sutherland, Andrea Illingworth, Iuri Marinov, Fernando Ortiz, John Andreasen, Dan Payne, Paul K. Wallace, Michael Keeney Tags: ICCS/ESCCA PNH Guidelines Source Type: research
ICCS/ESCCA consensus guidelines to detect GPI ‐deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 – clinical utility
Paroxysmal nocturnal hemoglobinuria (PNH) arises as a consequence of the non‐malignant clonal expansion of one or more hematopoietic stem cells with an acquired somatic mutation of the PIGA gene (Brodsky RA. Blood 113 (2009) 6522–6527). Progeny of affected stem cells are deficient in glycosyl phosphatidylinositol–anchored proteins (GPI‐APs). This deficiency is readily detected by flow cytometry. Though this seems straightforward, the clinical utility of this testing requires that the ordering clinician understand not only the characteristics of the test, but also the biology of the underlying disease, and the clini...
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: Amy E. Dezern, Michael J Borowitz Tags: ICCS/ESCCA PNH Guidelines Source Type: research
Too much of a good thing! additional studies in this issue
(Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: F. Preffer Tags: ICCS/ESCCA PNH Guidelines Source Type: research
Introduction to ICCS/ESCCA consensus guidelines to detect GPI ‐deficient cells in paroxysmal nocturnal hemoglobinuria and related disorders
(Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: Stephen J. Richards Tags: ICCS/ESCCA PNH Guidelines Source Type: research
Special Issue: Updated ICCS/ESCCA PNH guidelines
(Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Authors: F. Preffer Tags: ICCS/ESCCA PNH Guidelines Source Type: research
Issue Information
(Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - February 1, 2018 Category: Molecular Biology Tags: Issue Information Source Type: research
Human innate lymphoid cells (ILCs): Toward a uniform immune ‐phenotyping
Cytometry Part B: Clinical Cytometry, EarlyView. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - January 31, 2018 Category: Molecular Biology Authors: SaraTrabanelli
,
AlejandraGomez ‐Cadena
,
BérengèreSalomé
,
KatarzynaMichaud
,
DomenicoMavilio
,
Basile NicolasLandis
,
PeterJandus
,
CamillaJandus Source Type: research
---
Cytometry Part B: Clinical Cytometry, Ahead of Print. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - January 31, 2018 Category: Molecular Biology Source Type: research
Human innate lymphoid cells (ILCs): Toward a uniform immune ‐phenotyping
Helper innate lymphoid cells (ILCs), the most recently identified population of the ILC family, play a fundamental role in the restoration of tissue integrity, in the protection against infiltrating pathogens as well as in tumor immune‐surveillance. ILCs have been divided into three main subsets, ILC1, ILC2, and ILC3, that can be specifically activated by different signals coming either indirectly from pathogens or from other cell populations, including cancer cells. Following activation, ILCs are in turn able to promptly secrete a wide range of soluble mediators that modulate effector cell functions. The discovery and t...
Source: Cytometry Part B: Clinical Cytometry - January 31, 2018 Category: Molecular Biology Authors: Sara Trabanelli, Alejandra Gomez ‐Cadena, Bérengère Salomé, Katarzyna Michaud, Domenico Mavilio, Basile Nicolas Landis, Peter Jandus, Camilla Jandus Tags: Review Article Source Type: research
A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials
Cytometry Part B: Clinical Cytometry, EarlyView. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - January 23, 2018 Category: Molecular Biology Authors: FabienPitoiset
,
Mich èleBarbié
,
GuillaumeMonneret
,
CécileBraudeau
,
PierrePochard
,
IsabellePellegrin
,
JacquesTrauet
,
MyriamLabalette
,
DavidKlatzmann
,
MichelleRosenzwajg Source Type: research
Flow cytometric aberrancies in plasma cell myeloma and MGUS – correlation with laboratory parameters
Cytometry Part B: Clinical Cytometry, EarlyView. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - January 23, 2018 Category: Molecular Biology Authors: SarikaGupta
,
Nitin J.Karandikar
,
TimothyGinader
,
Andrew M.Bellizzi
,
Carol J.Holman Source Type: research
A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials
Cytometry Part B: Clinical Cytometry, EarlyView. (Source: Cytometry Part B: Clinical Cytometry)
Source: Cytometry Part B: Clinical Cytometry - January 23, 2018 Category: Molecular Biology Source Type: research
